TET1 and metastatic malignant neoplasm in the lymph nodes: Additionally, for overall survival (OS), TET1 expression (HR=2.712, 95%CI 1.627‐5.312; P < 0.001), microvascular involvement (HR=3.062, 95%CI 1.192‐4.936; P = 0.026), TNM stage (HR=1.987, 95%CI 1.576‐2.859; P < 0.001), lymph node metastasis (HR=2.854, 95%CI 1.051‐7.972; P = 0.047), and CA19‐9 expression (HR=1.973, 95%CI 1.374‐3.806; P = 0.025) were found to be independent risk factors (Table 1).